Skip to content

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Eli Lilly logo
Eli LillyLLY
0.1×0.0×
Pfizer logo
PfizerPFE
0.1×0.0×
Amgen logo
AmgenAMGN
0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.6×-0.3×
Biogen logo
BiogenBIIB
1.1×+0.6×

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Calculated from AnaptysBio, Inc.’s reported figures.

Based on the most recent quarter.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s cash ratio?
AnaptysBio, Inc. (ANAB) reported cash ratio of 6× in Q1 2026.
How has AnaptysBio, Inc.'s cash ratio changed year-over-year?
AnaptysBio, Inc.'s cash ratio increased by 166.0% year-over-year, from 2.2× to 6×.
What is the long-term trend for AnaptysBio, Inc.'s cash ratio?
Over 5 years (2020 to 2025), AnaptysBio, Inc.'s cash ratio has grown at a -13.4% compound annual growth rate (CAGR), from 12.6× to 6.2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.